🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Renal Cell Carcinoma Metastatic

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma NCT07645690EARLY Phase 13 sites📍 Beijing📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: CLEAR CAR-T cell injection Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology NCT07303725n/a1 site📍 Palo Alto Palo Alto Veterans Institute for Research Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial NCT03977571NA11 sites📍 Aarhus📍 Herlev📍 Odense Niels Fristrup · Tests: Cytoreductive nephrectomy, Tissue sampling GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases NCT04299646Phase 230 sites📍 Albi📍 Angers📍 Bordeaux Centre Francois Baclesse · Tests: Steretactic radiotherapy Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients NCT05817903Phase 223 sites📍 Brescia📍 Candiolo📍 Catania Consorzio Oncotech · Tests: Axitinib, Nivolumab Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 NCT07292168Phase 1, Phase 25 sites📍 Kazan'📍 Krasnoyarsk📍 Moscow Kidney Cancer Research Bureau · Tests: humanized monoclonal anti-FGFR1 antibody OM-RCA-01 An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma NCT07469683Phase 21 site📍 Seoul Yonsei University · Tests: SLC-3010 + Axitinib, Axitinib Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer NCT07128680Phase 12 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formul… Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT07011719Phase 3183 sites📍 Gilbert📍 Goodyear📍 Phoenix Arcus Biosciences, Inc. · Tests: Casdatifan, Cabozantinib, Placebo CAIX PET/ CT Guided Radiation Therapy in CcRCC. NCT07540260NA1 site📍 Beijing Peking University First Hospital · Tests: PETCT-guided radiation therapy Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024Phase 18 sites📍 Boston📍 Ann Arbor📍 St Louis Deciphera Pharmaceuticals, LLC · Tests: DCC-2812 IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms NCT03981497n/a1 site📍 Milan Francesco De Cobelli · Tests: Microwave ablation (MWA) A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma NCT06321250Phase 11 site📍 Beijing Jemincare · Tests: JMKX003948 REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma NCT07594106Phase 1, Phase 26 sites📍 Goodyear📍 Duarte📍 Tampa Regeneron Pharmaceuticals · Tests: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors NCT03972657Phase 1, Phase 224 sites📍 Gilbert📍 Phoenix📍 Tucson Regeneron Pharmaceuticals · Tests: REGN5678, Cemiplimab Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance NCT07636148n/a3 sites📍 Lyon📍 Créteil📍 Leiden Mark C Burgmans, MD PhD Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer NCT07227415Phase 1, Phase 2183 sites📍 Phoenix📍 Scottsdale📍 Fayetteville Pfizer · Tests: PF-08634404, Ipilimumab, Axitinib, Casdatifan Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors NCT05263050Phase 21 site📍 Philadelphia Fox Chase Cancer Center · Tests: Cabozantinib, Nivolumab Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC NCT06863311Phase 25 sites📍 La Jolla📍 Indianapolis📍 St Louis Karie Runcie · Tests: XL092, Nivolumab PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk NCT07175480Phase 21 site📍 Nanjing Jinling Hospital, China · Tests: Intermittent PD-1/PD-L1 ICI + VEGFR-TKI Measuring Oncological Value of Exercise and Statin NCT05796973Phase 31 site📍 Tampere Tampere University Hospital · Tests: Guided physical exercise, Atorvastatin, Independent exercise Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site📍 Adelaide SAPU NANO (US) LLC · Tests: Sapu003, Exemestane 25 MG
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy